Mepolizumab
- Generic Name
- Mepolizumab
- Brand Names
- Nucala
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 196078-29-2
- Unique Ingredient Identifier
- 90Z2UF0E52
- Background
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is comp...
- Indication
Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patie...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Hypereosinophilic Syndrome (HES), Severe Eosinophilic Asthma
- Associated Therapies
- -
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT04823585
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 30
- Registration Number
- NCT04765722
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1700
- Registration Number
- NCT04718389
- Locations
- 🇬🇧
GSK Investigational Site, Wishaw, United Kingdom
Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 169
- Registration Number
- NCT04607005
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- University of Newcastle, Australia
- Target Recruit Count
- 200
- Registration Number
- NCT04585997
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton, New South Wales, Australia
Residual Exacerbations With Mepolizumab
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Laval University
- Target Recruit Count
- 60
- Registration Number
- NCT04578171
Nation-wide Health Resource Consumption and Costs Associated With Mepolizumab
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 7938
- Registration Number
- NCT04550780
- Locations
- 🇫🇷
Uh Montpellier, Montpellier, France
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 40
- Registration Number
- NCT04512521
- Locations
- 🇩🇪
Hannover Medical School, Hanover, Niedersachsen, Germany
Mepolizumab for Eosinophilic Fasciitis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04305678
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT04276233
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.